LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

99.25 -0.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

97.16

Max

100.15

Põhinäitajad
By Trading Economics
Sissetulek	64M 118M
Müük	-29M 377M
P/E Sektori keskmine	23.512 50.102
Aktsiakasum	1.46
Kasumimarginaal	31.383
Töötajad	1,193
EBITDA	-17M 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+3.65% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	684M 6.4B
Eelmine avamishind	99.66
Eelmine sulgemishind	99.25

Uudiste sentiment

By Acuity

18%

82%

23 / 344 Pingereas Healthcare

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2026, 21:33 UTC

Tulu

Correction to Salesforce 1Q Sales, Profit Rise Article

27. mai 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. mai 2026, 20:18 UTC

Tulu

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. mai 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. mai 2026, 21:08 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. mai 2026, 21:02 UTC

Tulu

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. mai 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. mai 2026, 20:55 UTC

Tulu

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. mai 2026, 20:48 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. mai 2026, 20:45 UTC

Tulu

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

27. mai 2026, 20:32 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. mai 2026, 20:30 UTC

Tulu

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. mai 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. mai 2026, 20:22 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:16 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. mai 2026, 20:13 UTC

Tulu

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

3.65% tõus

12 kuu keskmine prognoos

Keskmine 103.71 USD 3.65%

Kõrge 115 USD

Madal 90 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

23 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.